|
| | HJ0013 | | LRB097 10564 RPM 50912 r |
|
|
1 | | HOUSE JOINT RESOLUTION
|
2 | | WHEREAS, Krabbe disease, also known as Globoid Cell |
3 | | Leukodystrophy, is an inherited neurodegenerative lysosomal |
4 | | enzyme disorder affecting the central and peripheral nervous |
5 | | systems caused by a defect in the GALC gene; persons with this |
6 | | gene defect do not make enough of an enzyme called |
7 | | galactosylceramidase; the body needs this enzyme to make |
8 | | myelin, the material that surrounds and protects nerve fibers; |
9 | | without the enzyme, myelin breaks down and as a result, brain |
10 | | cells die and nerves in the brain and other body areas cannot |
11 | | function properly; and
|
12 | | WHEREAS, The symptoms of the infantile form of Krabbe |
13 | | disease usually begin before the age of one year; initial signs |
14 | | and symptoms typically include irritability, muscle weakness, |
15 | | feeding difficulties, episodes of fever without any sign of |
16 | | infection, stiff posture, and slowed mental and physical |
17 | | development; with disease progression, muscles continue to |
18 | | weaken, affecting the infant's ability to move, chew, swallow, |
19 | | and breathe; affected infants also experience vision loss and |
20 | | seizures; death usually occurs before the age of 2 years; and
|
21 | | WHEREAS, Though the condition is considered very rare (1 in |
22 | | 100,000 births in the United States) it is estimated that the |
23 | | carrier rate in the general population is estimated to be 1 in |